晚期非小细胞肺癌病人一线治疗的优化策略

Optimization strategies of first-line treatment of patients with advanced non-small cell lung cancer

肺癌是全球头号癌症杀手,合理优化晚期非小细胞肺癌病人的药物治疗策略,有望改善病人的生存预后。至今,含铂两药化疗仍是非小细胞肺癌群体有效率最高的治疗首选;对于选择性人群,如表皮生长因子受体突变者,靶向药物表皮生长因子受体酪氨酸激酶抑制剂更具优势。两者应用新模式和策略仍在进一步研究和完善中。

Lung cancer is a leading cause of cancer-related death worldwide.It is possible to achieve marginal improvement in overall survival of patients with advanced non-small-cell lung cancer（NSCLC） by optimizing strategies of drugs treatment.The platinum-based doublet chemotherapy has been considered as the standard first-line treatment for NSCLC with the highest treatment efficacy.Erlotinib and gefitinib appear to be especially effective for tumors with gene mutations of activated epidermal growth factor receptor.Further investigations with valid comparison groups are necessary in order to better define their optimal treatment modality.